OPTIVAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPTIVAR (OPTIVAR).
Selective histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils, reducing allergic response.
| Metabolism | Hepatic via glucuronidation; minor CYP450 involvement. Elimination half-life: ~5-7 hours. |
| Excretion | Primarily renal excretion as unchanged drug (approximately 60-70% of administered dose is excreted unchanged in urine within 48 hours). The remainder is eliminated via biliary/fecal routes (30-40%), largely as unchanged drug with minor metabolites. |
| Half-life | Terminal elimination half-life: 6-9 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe renal insufficiency). |
| Protein binding | Approximately 70-80% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution: approximately 2.5-4.5 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Ophthalmic solution: Systemic bioavailability is low (less than 10% of administered dose) due to local administration and limited absorption; negligible oral bioavailability (drug is for topical ophthalmic use only). |
| Onset of Action | Ophthalmic solution: Onset of relief of ocular itching within minutes; peak effect at 30-60 minutes. |
| Duration of Action | Duration of action: 8-12 hours after a single dose, allowing twice-daily dosing for allergy symptom control. |
One drop (approximately 0.05 mL of 0.1% ophthalmic solution) in each affected eye twice daily, approximately every 6 to 8 hours.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment based on current data. |
| Liver impairment | No dose adjustment required for hepatic impairment based on current data. |
| Pediatric use | Children 3 years and older: same as adult dose (one drop in each affected eye twice daily). Safety and efficacy in children under 3 years have not been established. |
| Geriatric use | No specific dose adjustment required; use same dose as for younger adults. Caution with concomitant medications and renal function as part of general geriatric care. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OPTIVAR (OPTIVAR).
| Breastfeeding | Unknown if excreted in human milk. Caution advised; M/P ratio not determined. |
| Teratogenic Risk | Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies. Risk cannot be ruled out; use only if clearly needed. |
| Fetal Monitoring | Monitor for maternal CNS depression, increased intraocular pressure, or cardiovascular effects. No specific fetal monitoring required. |
■ FDA Black Box Warning
None.
| Common Effects | Hypoglycemia low blood glucose level Headache Nausea Diarrhea Flatulence |
| Serious Effects |
["Hypersensitivity to azelastine or any component of the formulation."]
| Precautions | ["Avoid contact with soft contact lenses; contains benzalkonium chloride which may be absorbed by lenses.","May cause transient burning/stinging upon instillation.","Use with caution in patients with hepatic impairment."] |
Loading safety data…
| Fertility Effects | No known adverse effects on fertility in animal studies; human data insufficient. |